Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT05653011
Recruiting Observational

Predictors of Prognosis in IBD Patients

NCT05653011 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seoul National University Bundang Hospital
Phase
Observational
Started
2013-03-11
Last updated
2026-04-24

Condition(s) studied

Inflammatory Bowel DiseasesUlcerative ColitisCrohn Disease

Investigational drug(s) / intervention(s)

Endoscopic biopsy

Endoscopic biopsy: When patients have colonoscopy or sigmoidoscopy for evaluation of their disease course, biopsied samples are collected. In the IBD group, samples are obtained at endoscopically active and/or inactive lesions. In the control group, samples are obtained at endoscopically normal lesions.

Study summary

A study of clinical characteristics and potential prognostic factors in inflammatory bowel disease

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * control group: Patients who do not have colitis, cancer, and advanced polyp (the number of polyps ≥ 3, the size of polyps ≥ 1cm, high-grade adenoma, villous adenoma) * TNF-α inhibitor-naive IBD group: IBD patients who do not have a history of TNF-α inhibitor treatment * TNF-α inhibitor-treated IBD group: IBD patients who are treated with TNF-α inhibitor Exclusion Criteria: * Age under 18 years * Patients who were treated with antibiotics or probiotics within the last 3 months

Primary outcome measure(s)

  • The expression level of multiple markers associated with IBD activity or prognosis — baseline (at the time of enrollment)
    The expression level of multiple markers was evaluated through RT-qPCR using endoscopically biopsied samples or blood samples. Markers include TGF-b, SLUG, SNAIL, E-cadherin, vimentin, OLFM4, LGR5, a-SMA, FSP1, IL-17A, IL-23, TGF-b, IL-6, IFN-r, IL-1b, FOXP3, PD-1, CD68, PAD4, COL3A1, TIMP3, LOX, ACTA2, ITGB6, CAV-1 etc.

Trial sites (1)

FacilityCityRegionStatus
Seoul National University Bundang Hospital Seongnam-si Gyeonggi-do Recruiting

More Seoul National University Bundang Hospital trials in South Korea

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes Recruiting
Clinical Trial for the Evaluation of the Efficacy and Safety of EDL on Dyspepsia Recruiting
SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary Resection Recruiting
Effectiveness of Video-Based Movement Analysis-Guided Personalized Rehabilitation in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Enrolling by invitation
Surface Electromyographic Analysis of Normal Swallowing in Children: An Exploratory Study Starting soon

Other trials for the same condition

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease Recruiting
Long-term Efficacy and Safety of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis Enrolling by invitation
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) Recruiting
A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05653011 on ClinicalTrials.gov ↗ ← All trials in South Korea